KCS

Alzheimer’s disease (AD) is one of the degenerative brain diseases that occur with aging. As the aging society of mankind gradually deepens, it becomes a bigger social problem. In addition, since the exact cause of AD has not yet been found, treatment of the disease remains a serious problem. Here we introduced repositioning of HEPES (4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid). HEPES is a well-known buffer solution for material mainly used for cell culture because of its good effect of maintaining pH. However, in this study, we demonstrated a new efficacy for HEPES in disaggregating amyloid beta plaques, which are presumed to be the cause of AD. In this work, we proved that HEPES can disaggregate amyloid beta plaques using several probes capable of detecting amyloid beta plaques. These results showed better efficiency than EPPS ((4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid), which was previously reported as a disaggregating agent of amyloid beta plaques. Furthermore, in order to improve the frequent drug intake, which is a very big disadvantage in Alzheimer's disease treatment, a drug release system that is released sustainably for about 2 weeks was introduced by hybridizing it with Eudragit S 100, a biocompatible polymer.